A C Hesseling
Overview
Explore the profile of A C Hesseling including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
116
Citations
2505
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marthinus A, Wademan D, Saule Z, Hirsch-Moverman Y, Viljoen L, Winckler J, et al.
IJTLD Open
. 2025 Jan;
2(1):13-18.
PMID: 39802236
Background: TB preventive treatment (TPT) prevents the development of TB disease in individuals at risk of progression from infection to disease. However, implementation of TPT for children is poor in...
2.
Anthony M, Johnson L, van Niekerk M, Mfwaze A, Bavuma B, Hesseling A, et al.
IJTLD Open
. 2024 Nov;
1(11):495-500.
PMID: 39544879
Background: Respiratory illnesses, including pulmonary TB (PTB), cause significant morbidity. We aimed to understand the health-related quality of life (HRQoL) of children with presumptive PTB. Methods: Children aged 0-13 years...
3.
Palmer M, van der Zalm M, Schaaf H, Goussard P, Morrison J, Seddon J, et al.
Int J Tuberc Lung Dis
. 2024 Oct;
28(11):547-553.
PMID: 39468018
<sec><title>INTRODUCTION</title>SHINE (Shorter Treatment for Minimal Tuberculosis in Children) was the first Phase 3 paediatric TB treatment-shortening trial. Robust chest X-ray (CXR) classification methods were integral to excluding severe disease for...
4.
Wademan D, Draper H, Purchase S, Palmer M, Hesseling A, van der Laan L, et al.
IJTLD Open
. 2024 Jul;
1(2):69-75.
PMID: 38966689
Background: We evaluated the palatability and acceptability of a 100 mg dispersible and a non-dispersible 250 mg levofloxacin (LVX) tablet formulation in children. Methods: Perform was a randomised, open-label, cross-over...
5.
Wademan D, Saule Z, Marthinus A, Viljoen L, Nortier E, Hughes J, et al.
Int J Tuberc Lung Dis
. 2024 Apr;
28(5):256-258.
PMID: 38659140
No abstract available.
6.
Myburgh H, Kaur M, Kaur P, Santos V, Almeida C, Hoddinott G, et al.
Public Health Action
. 2023 Dec;
13(4):162-168.
PMID: 38077722
Background: Brazil, India and South Africa are among the top 30 high TB burden countries globally and experienced high rates of SARS-CoV-2 infection and mortality. The COVID-19 response in each...
7.
Taneja R, Nahata M, Scarim J, Pande P, Scarim A, Hoddinott G, et al.
Int J Tuberc Lung Dis
. 2023 Oct;
27(11):810-815.
PMID: 37880886
Tablets are the most widely available dosage form for the treatment of TB; however, adult tablets fail to meet the needs of young children who cannot swallow these tablets or...
8.
Myburgh H, Meehan S, Wademan D, Osman M, Hesseling A, Hoddinott G
Public Health Action
. 2023 Sep;
13(3):97-103.
PMID: 37736584
Background: The global COVID-19 pandemic has reversed many of the hard-won gains made in TB programmes and the associated reduction in the number of TB deaths, case notifications and incidence...
9.
Maritz E, Montepiedra G, Mitchell C, Madhi S, Bobat R, Violari A, et al.
Int J Tuberc Lung Dis
. 2023 Jul;
27(8):619-625.
PMID: 37491747
P1041 was a randomised, placebo-controlled isoniazid prophylaxis trial in South Africa. We studied predictors for TB in HIV-exposed children participating in the P1041 trial. We included data from entry until...
10.
Strauss M, Wademan D, Mcinziba A, Hoddinott G, Rafique M, Jola L, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):520-529.
PMID: 37353873
TB preventive therapy (TPT) is critical for ending TB, yet implementation remains poor. With new global guidelines expanding TPT eligibility and regimens, we aimed to understand TPT preferences among children,...